The aspirin in reducing events in the elderly trial: Statistical analysis plan
Rationale: Aspirin has positive and negative effects on a number of age-related chronic conditions and there is uncertainty regarding its role in primary prevention in people aged 70 years and over. Aims: To assess whether daily active treatment of 100 mg enteric-coated aspirin will extend the durat...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
Wiley-Blackwell Publishing Asia
2018
|
| Online Access: | http://hdl.handle.net/20.500.11937/67682 |
| _version_ | 1848761630132797440 |
|---|---|
| author | Wolfe, R. Murray, A. Woods, R. Kirpach, B. Gilbertson, D. Shah, R. Nelson, M. Reid, Christopher Ernst, M. Lockery, J. Donnan, G. Williamson, J. McNeil, J. |
| author_facet | Wolfe, R. Murray, A. Woods, R. Kirpach, B. Gilbertson, D. Shah, R. Nelson, M. Reid, Christopher Ernst, M. Lockery, J. Donnan, G. Williamson, J. McNeil, J. |
| author_sort | Wolfe, R. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Rationale: Aspirin has positive and negative effects on a number of age-related chronic conditions and there is uncertainty regarding its role in primary prevention in people aged 70 years and over. Aims: To assess whether daily active treatment of 100 mg enteric-coated aspirin will extend the duration of disability-free life in healthy older participants. Design: A double-blind, randomized, placebo-controlled primary prevention trial undertaken in Australia and the United States with careful adjudication of endpoints including stroke. Study outcome: In Australia 16,703 individuals were recruited through general practices across five states and territories, and in the United States, 2411 participants were recruited through 34 clinical sites across the country. Follow-up of participants will finish at the end of 2017 with average follow-up exceeding 4.25 years per person. Discussion: The statistical analysis plan for ASPREE, finalized after closure of recruitment but before the end of patient follow-up, outlines the primary analyses and a range of subgroup and sensitivity analyses. (International Standard Randomized Controlled Trial Number Register ISRCTN83772183 and clinicaltrials.gov Number NCT01038583). |
| first_indexed | 2025-11-14T10:34:43Z |
| format | Journal Article |
| id | curtin-20.500.11937-67682 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T10:34:43Z |
| publishDate | 2018 |
| publisher | Wiley-Blackwell Publishing Asia |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-676822018-09-28T03:35:24Z The aspirin in reducing events in the elderly trial: Statistical analysis plan Wolfe, R. Murray, A. Woods, R. Kirpach, B. Gilbertson, D. Shah, R. Nelson, M. Reid, Christopher Ernst, M. Lockery, J. Donnan, G. Williamson, J. McNeil, J. Rationale: Aspirin has positive and negative effects on a number of age-related chronic conditions and there is uncertainty regarding its role in primary prevention in people aged 70 years and over. Aims: To assess whether daily active treatment of 100 mg enteric-coated aspirin will extend the duration of disability-free life in healthy older participants. Design: A double-blind, randomized, placebo-controlled primary prevention trial undertaken in Australia and the United States with careful adjudication of endpoints including stroke. Study outcome: In Australia 16,703 individuals were recruited through general practices across five states and territories, and in the United States, 2411 participants were recruited through 34 clinical sites across the country. Follow-up of participants will finish at the end of 2017 with average follow-up exceeding 4.25 years per person. Discussion: The statistical analysis plan for ASPREE, finalized after closure of recruitment but before the end of patient follow-up, outlines the primary analyses and a range of subgroup and sensitivity analyses. (International Standard Randomized Controlled Trial Number Register ISRCTN83772183 and clinicaltrials.gov Number NCT01038583). 2018 Journal Article http://hdl.handle.net/20.500.11937/67682 10.1177/1747493017741383 Wiley-Blackwell Publishing Asia restricted |
| spellingShingle | Wolfe, R. Murray, A. Woods, R. Kirpach, B. Gilbertson, D. Shah, R. Nelson, M. Reid, Christopher Ernst, M. Lockery, J. Donnan, G. Williamson, J. McNeil, J. The aspirin in reducing events in the elderly trial: Statistical analysis plan |
| title | The aspirin in reducing events in the elderly trial: Statistical analysis plan |
| title_full | The aspirin in reducing events in the elderly trial: Statistical analysis plan |
| title_fullStr | The aspirin in reducing events in the elderly trial: Statistical analysis plan |
| title_full_unstemmed | The aspirin in reducing events in the elderly trial: Statistical analysis plan |
| title_short | The aspirin in reducing events in the elderly trial: Statistical analysis plan |
| title_sort | aspirin in reducing events in the elderly trial: statistical analysis plan |
| url | http://hdl.handle.net/20.500.11937/67682 |